Overview

This trial is active, not recruiting.

Condition indolent non hodgkin lymphoma
Treatments lenalidomide, rituximab
Phase phase 2
Target CD20
Sponsor Gruppo Italiano Studio Linfomi
Start date April 2009
End date December 2010
Trial size 44 participants
Trial identifier NCT01830478, INFL08

Summary

The purpose of this study is to determine whether lenalidomide in association with rituximab is effective in the treatment of patients with indolent non follicular NHL relapsed after >=2, but less than 4 prior lines of (immuno)chemotherapy.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Lenalidomide 20 mg once daily on days 1-21 of 28 days cycle for up to 6 courses and Rituximab 375 mg/m2 at day 14 of every course.
lenalidomide Revlimid
Lenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles
rituximab Mabthera
Rituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles

Primary Outcomes

Measure
Assess the efficacy
time frame: Two weeks after the completion of Rituximab + Lenalidomide

Secondary Outcomes

Measure
Assess the safety
time frame: From start of treatment for all follow up period (18 months)

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: - Histological confirmed diagnosis of B-Cell non follicular NHL according to REAL/WHO Classification: small lymphocytic lymphoma, lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia, nodal marginal zone lymphoma, splenic marginal zone lymphoma, extranodal non-gastric marginal zone lymphoma - Availability of tissue biopsy mandatory when suspected pathological sites (nodal or extranodal) are easily accessible and in presence of extranodal non-gastric marginal or nodal marginal zone lymphoma diagnosis. In the other cases bone marrow biopsy, when representative, may be considered sufficient for defining lymphoma histotype - Disease relapsing after >=2, but less than 4 prior lines of (immuno)chemotherapy. At least one of previous treatment had to include rituximab - Presence of at least one of the following criteria for the definition of active disease: systemic symptoms, bulky disease, progressive marrow failure and/or splenomegaly and/or lymph adenopathy - Age 18-75 - Life expectancy > 6 months - Eastern Cooperative Oncology Group (ECOG) <=2 - Left ventricular ejection fraction (LVEF) >=45% - Creatinine clearance >= 50 mL/min calculated by Cockcroft-Gault estimation; patients with creatinine clearance >= 30 and < 50 mL/min, at physician discretion could enter the study starting at lenalidomide dose level -2 (10 mg) - Total bilirubin up to 2 x upper limit of normal(ULN). Total bilirubin values higher than 2 x ULN are admitted if related to localization of the disease - Alkaline phosphatase up to 2 x ULN and transaminases up to 3 x ULN - Female and male patients must agree to participate in pregnancy prevention program signing informed Consent (paragraph 5.4.) - Written informed Consent Exclusion Criteria: - Previously untreated patients - Patients with diagnosis of typical Chronic Lymphocytic Leukemia (CLL) - Women and men not agreeing to take adequate contraceptive precautions during and for at least 4 weeks after cessation of therapy - Pregnant or lactating women - History of other malignancies within 3 years prior to study entry except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer, low grade, early stage localized prostate cancer treated surgically with curative intent, good prognosis ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone with curative intent - Active bacterial, viral or fungal infection requiring systemic therapy - Concurrent co-morbid medical condition which might exclude administration of therapy - Cardiac insufficiency (NYHA grade III/IV) - Myocardial infarction within 6 months of entry on the study - Severe chronic obstructive pulmonary disease with hypoxemia - Severe diabetes mellitus difficult to control with adequate insulin therapy - Hypertension that is difficult to control - Creatinine clearance < 30 mL/min calculated by Cockcroft-Gault estimation - Absolute neutrophil count (ANC) <= 1 x 109/L, unless due to lymphoma involvement and not responding to 5 days of Granulocyte colony-stimulating factor (G-CFS) treatment - Platelets count <=75.000/mm3, unless due to lymphoma involvement - HIV and Hepatitis B virus (HBV) positivity - Hepatitis C virus (HCV) positivity in presence of high level of virus replication and Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) > x 2.5 ULN - Central nervous system (CNS) involvement by lymphoma - Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins - Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent

Additional Information

Official title Phase II Study of Lenalidomide in Combination With Rituximab (R) for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL).
Principal investigator Stefano Sacchi, MD
Description Single arm, multicenter, open-label study divided in two phases: 1. Induction phase; 2. Follow-up phase. Enrolled patients will start the induction phase and receive the courses of R-Lenalidomide. At the end of the third cycle of R-Lenalidomide (week 12 of the study), the patients will be evaluated for tumor response (complete assessment); the patients with Progressive Disease (PD) will be withdrawn of the study. Two weeks after the end last courses of R-Lenalidomide (week 26 of the study) patients will be evaluated for tumor response (complete assessment). Patients with Complete Response (CR) and Partial Response (PR), and with a stable disease will undergo the follow up phase, while patients with PD will be withdrawn of the study.
Trial information was received from ClinicalTrials.gov and was last updated in April 2013.
Information provided to ClinicalTrials.gov by Gruppo Italiano Studio Linfomi.